H.C. Wainwright analyst Andrew Fein maintained a Buy rating on ACADIA Pharmaceuticals (ACAD – Research Report) today and set a price target of $27.00.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Andrew Fein’s rating is based on several factors that highlight the potential growth and positive impact of ACADIA Pharmaceuticals’ product, Daybue. Despite a slight revenue miss, the patient base for Daybue has shown a steady increase, indicating a promising growth trajectory. Factors contributing to this outlook include a gradual increase in net pricing, reduced discontinuations, and a strategic focus on expanding the patient base. Additionally, the anticipated European launch in 2026 is expected to further enhance market penetration.
Real-world feedback from patients and caregivers has been overwhelmingly positive, with reports of improved quality of life, including better motor function, sleep, and overall well-being. These improvements, coupled with increased awareness and diagnosis rates, suggest that Daybue’s sales are on track to continue growing. The combination of these elements supports Fein’s Buy rating for ACADIA Pharmaceuticals, as the company appears well-positioned for future success.
According to TipRanks, Fein is a 4-star analyst with an average return of 3.1% and a 43.41% success rate. Fein covers the Healthcare sector, focusing on stocks such as Neurocrine, Arvinas Holding Company, and Insmed.
In another report released today, RBC Capital also maintained a Buy rating on the stock with a $26.00 price target.